LONDON — China’s biotech sector is steadily moving beyond a “me-too” approach to drug development thanks to a surge in quality talent, regulatory flexibility and a level of speed that’s tough to rival, industry executives said …
Roche places a $1bn bet on C4T degrader-antibody conjugates
Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.

